Fig. 5

Using IVIS imaging for protection models. a Monoclonal antibody protection prior to infection. Treatment with 300 μg of AB317 before IV injection of parasites, confers > 99% inhibition of liver stage development as measured by IVIS. There is dose dependent reduction of liver stage development as AB317 treatment decreases. The numbers on top of each histogram represents the percent inhibition compared to the parasite load measured in naïve mice. b Treatment with AB-317 before and after sporozoite challenge. Treatment before challenge inhibits liver stage development, while treatment after challenge has no effect. c Sterile immunity, as assessed by lack of blood parasitaemia, after mAb treatment followed by exposure to mosquito bites. Kaplan–Meier curves demonstrate dose-dependent protection by AB317, with complete protection with 300 μg. 1245, a mAb directed against an irrelevant antigen, is used as a negative control for mAb treatment. Dashed lines represent background bioluminescence levels obtained from uninfected mice injected with luciferin